Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection

Zhang, Huixia; Xie, Ruyu; Zhang, Han; Sun, Ruiqi; Li, Shujun; Xia, Chuandao; Li, Zexing; Zhang, Lilin; Guo, Yanyu; Huang, Jinhai

doi:10.1016/j.psj.2023.102662

Cited by 9 publications

(8 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability to use yeast as a vaccine vector has been explored in different studies for the therapy of different types of cancer, as immunomodulators, and for the treatment or prophylaxis of infectious diseases [ 15 , 17 , 72 ]. In this context, yeast can also be used to carry RNA molecules.…”

Section: Biodelivery Of Mrna Vaccines By Yeastsmentioning

confidence: 99%

See 1 more Smart Citation

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Silva,

de Sousa,

de Macêdo

et al. 2023

Vaccines

View full text Add to dashboard Cite

In the last decades, technological advances for RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct the translation of the antigen responsible for activating the desired immune response. The success of RNA vaccines depends on the delivery vehicle. Among the systems, yeasts emerge as a new approach, already employed to deliver protein antigens, with efficacy demonstrated through preclinical and clinical trials. β-glucans and mannans in their walls are responsible for the adjuvant property of this system. Yeast β-glucan capsules, microparticles, and nanoparticles can modulate immune responses and have a high capacity to carry nucleic acids, with bioavailability upon oral immunization and targeting to receptors present in antigen-presenting cells (APCs). In addition, yeasts are suitable vehicles for the protection and specific delivery of therapeutic vaccines based on RNAi. Compared to protein antigens, the use of yeast for DNA or RNA vaccine delivery is less established and has fewer studies, most of them in the preclinical phase. Here, we present an overview of the attributes of yeast or its derivatives for the delivery of RNA-based vaccines, discussing the current challenges and prospects of this promising strategy.

show abstract

Section: Biodelivery Of Mrna Vaccines By Yeastsmentioning

confidence: 99%

“…In this case, the default promoter is CMV, derived from Cytomegalovirus [ 10 ]. The combined nucleic acid vaccine, yeast-carried, is effectively expressed and can be successfully delivered for immunized animals [ 72 ].…”

Section: Biodelivery Of Mrna Vaccines By Yeastsmentioning

confidence: 99%

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Silva,

de Sousa,

de Macêdo

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Zhang et al (2023) showed the feasibility of combining DNA-RNA sequences with hemagglutinin as a target gene (rH9-DNA-RNA) in the same plasmid and using S. cerevisiae as a vaccine vehicle. The combined nucleic acids were effectively expressed and successfully delivered into the intestinal cells of orally immunized animals [36].…”

Section: Biodelivery Of Mrna Vaccines By Yeastsmentioning

confidence: 99%

“…The vaccine antigen, HA protein, was also expressed. [36] shRNA (short hairpin RNA); siRNA (short interfering RNA); GeRPs (β1,3-d-glucan-encapsulated siRNA particles); Tnf-α (tumour necrosis factor α); IL-1β (interleukin-1β); miRNA (microRNA); SGF (Simulated gastric fluid).…”

Section: Oral Yeast-based Immunization For Rna Vaccinesmentioning

confidence: 99%

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Silva¹,

Souza²,

Macêdo³

et al. 2023

Preprint

View full text Add to dashboard Cite

In the last decades, technological advances related to RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct the translation of the antigen responsible for activating the desired immune response. The success of RNA vaccines depends on the delivery vehicle employed. Among the systems, yeasts emerge as a new approach to a natural delivery platform. The presence of β-glucans and mannans in its wall is responsible for the adjuvant action of this system. Yeasts are already employed to deliver protein antigens, with success and efficacy demonstrated through pre-clinical and clinical trials. Yeast β-glucan capsules, microparticles, and nanoparticles are capable of modulating host immune responses and have a high capacity to carry RNA and small molecules, with bioavailability upon oral immunization and with targeting to receptors present in anti-gen-presenting cells (APCs). Besides, yeasts are interesting vehicles for the protection and specific delivery of therapeutic vaccines based on shRNA or dsRNA. In this review, we present an overview of the attributes of yeast or its derivatives for the delivery of RNA-based vaccines, discussing their current challenges and prospects for using this promising strategy.

show abstract

“…Even yeasts such as Saccharomyces cerevisiae or particles derived from its wall components have shown promise for RNAi delivery [ 223 ]. An interesting approach with this delivery system is the construction of plasmids that allow the simultaneous delivery of DNA and RNAi vaccines [ 224 ]. Thus, it would be possible to develop strategies that employ the delivery of HPV oncogenes as antigens in DNA vaccines associated with RNAi sequences targeting markers such as CSF1, aiming at blocking neoplasias in their earliest stages.…”

Section: Antigen-presenting Cells As Vaccine Targets For the Treatmen...mentioning

confidence: 99%

Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment

et al. 2023

View full text Add to dashboard Cite

The understanding of the relationship between immunological responses and cancers, especially those related to HPV, has allowed for the study and development of therapeutic vaccines against these neoplasias. There is a growing number of studies about the composition and influence of the tumor microenvironment (TME) in the progression or establishment of the most varied types of cancer. Hence, it has been possible to structure immunotherapy approaches based on therapeutic vaccines that are even more specific and directed to components of TME and the immune response associated with tumors. Among these components are dendritic cells (DCs), which are the main professional antigen-presenting cells (APCs) already studied in therapy strategies for HPV-related cancers. On the other hand, tumor-associated macrophages are also potential targets since the profile present in tumor infiltrates, M1 or M2, influences the prognosis of some types of cancer. These two cell types can be targets for therapy or immunomodulation. In this context, our review aims to provide an overview of immunotherapy strategies for HPV-positive tumors, such as cervical and head and neck cancers, pointing to TME immune cells as promising targets for these approaches. This review also explores the potential of immunotherapy in cancer treatment, including checkpoint inhibitors, cytokine immunotherapies, immunotherapy vaccines, and cell therapies. Furthermore, it highlights the importance of understanding the TME and its effect on the design and achievement of immunotherapeutic methods.

show abstract

Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection

Cited by 9 publications

References 52 publications

RNA Vaccines: Yeast as a Novel Antigen Vehicle

RNA Vaccines: Yeast as a Novel Antigen Vehicle

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment

Contact Info

Product

Resources

About